Delving into the Latest Updates on Sirius Therapeutics Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

siRNA

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

siRNA	8

Top 5 Target	Count

PCSK9(Proprotein convertase subtilisin kexin type 9)	1
F11(Coagulation factor XI)	1

主要目的：评价单剂量皮下给药后SRSD101 在LDL C 正常或升高的中国受试者中的安全性和耐受性。次要目的：评价单剂量皮下给药后SRSD101 及其血浆代谢产物（如适用）在LDL C 正常或升高的中国受试者中的药代动力学（PKPK）特征；评价单剂量皮下给药后SRSD101 在LDL C 正常或升高的中国受试者中的药效学（PDPD）特征；评价单剂量皮下给药后SRSD101 在LDL C 正常或升高的中国受试者中的免疫原性（ADAADA）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of SRSD101 in Chinese subjects with normal or elevated LDL C after a single subcutaneous dose. Secondary objectives: To evaluate the pharmacokinetic (PKPK) characteristics of SRSD101 and its plasma metabolites (if applicable) in Chinese subjects with normal or elevated LDL C after a single subcutaneous dose; to evaluate the pharmacodynamic (PDPD) characteristics of SRSD101 in Chinese subjects with normal or elevated LDL C after a single subcutaneous dose; to evaluate the immunogenicity (ADAADA) characteristics of SRSD101 in Chinese subjects with normal or elevated LDL C after a single subcutaneous dose.

Start Date-

Sponsor / Collaborator

Sirius Therapeutics Co., Ltd.

100 Clinical Results associated with Sirius Therapeutics Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sirius Therapeutics Co., Ltd.

Login to view more data

100 Deals associated with Sirius Therapeutics Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sirius Therapeutics Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

5

1

IND Application

Phase 1

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SRSD-107 ( F11 )	Arterial thrombosis More	Phase 1
SRSD-101 ( PCSK9 )	Primary hypercholesterolemia More	IND Approval
SRSD-216	Cardiovascular Diseases More	IND Application
SRSD-229	Cardiovascular Diseases More	Preclinical
SRSD-131	Cardiovascular Diseases More	Preclinical